Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (May 2020)
32 slides from Cocrystal Pharma's investor presentation, May 11, 2020
Slide 1: Investor Presentation May 2020
NASDAQ: COCP. cocrystalpharma.com CCRYSTAL | Investor Presentation PHARMA,INC. May 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. (“Merck”), including the expected accelerat
Slide 3: Management and Scientific Advisory Board
Gary Wilcox, Ph.D. o_ ge Cialis: tadalafil UCLA icos XOMA Chairman and Chief Executive Officer + Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis Sam Lee, Ph.D. President + Over 25 years of anti-infective drug discovery research experience a
Slide 4: Corporate Overview
1S Corporate Overview Target Diseases Clinical Stage Antiviral Company Influenza Proprietary Drug Discovery Platform Hepatitis Merck Influenza Collaboration Coronavirus (COVID-19) Norovirus (Gastroenteritis)
Slide 5: Technology Platform
Technology Platform Based on Nobel Prize-winning technology * Near-atomic resolution + X-ray quality crystal production * Hit-to-lead process + Lead optimization i + Drug pocket selection ¢ Drug candidates Technology and Drug Discovery Platform Drug Discovery Platform Crystal Production Expression &
Slide 6: Robust Development Pipeline
Robust Development Pipeline Program Discovery | Pre Phase 1 Phase 2a Phase 2b Phase 3 CC-31244 — men Ualvers SC (HCV) University of MD (Pan-genotypic NS5B NNI) CC-42344 (Influenza A PB2 Inhibitor) Influenza A/B inhibitor =» In collaboration with r=) MERCK Influenza Coronavirus Replication and (COVID
Slide 7: Merck/Cocrystal Team Initiates Influenza Collaboration
A NS Lol Merck/Cocrystal Team Initiates Influenza Collaboration Recognized revenue of $6.56 million in 2019, eligible to receive up to $156 million in milestone payments and royalties (undisclosed) on product sales Exclusive license and collaboration agreement to discover and develop certain proprie
Slide 8: Overview | Antiviral Programs: Coronavirus
Overview | Antiviral Programs: Coronavirus
Slide 9: COVID-19: Current Global Pandemic
COVID-19: Current Global Pandemic as of 5/8/2020 with No FDA Approved Therapeutic or Vaccine Total Confirmed Global Deaths 272,286 Coronavirus COVID-19 Glol e Center for Systems S ce and Engineering (CSSE) at Johns Hopkins University (JHU) as of 5.8.20 9 C@CRYSTAL PHARMA , ING
Slide 10: Kansas State University Research Foundation Agreements
A NS Lol Kansas State University Research Foundation Agreements Cocrystal acquires exclusive patent rights and know-how for coronavirus and norovirus therapeutics for humans use License agreements with Kansas State University Research Foundation (KSURF) to further develop certain proprietary broad-s
Slide 11: Aggressively Pursuing Development of Novel Antiviral Therapies for COVID-19
roi Aggressively Pursuing Development of Novel Antiviral 7 Therapies for the Treatment of COVID-19 Infections Potential to be effective treatment for COVID-19 (SARS-CoV-2) Develop COVID-19 (SARS-CoV-2) inhibitors using proprietary platform technology ° Targeting viral replication complex and proteas
Slide 12: Overview | Antiviral Programs: Hepatitis C
12 Overview | Antiviral Programs: Hepatitis C
Slide 13: HCV Is Still a Global Issue
1S HCV Is Still a Global Issue 71 Million 400,000 , A people die annually people infected globally frarirelated causes! Only 20% Only 2% of infected patients of infected patients have been diagnosed! are being treated! 1: Polaris Observatory, 2019 13
Slide 14: Current HCV Market Overview
SS xT Current HCV Market Overview * Limitations of existing long-term HCV therapies: . Cocrystal’s HCV Strategy Lead program CC-31244, Phase 2a study for the treatment of Hepatitis C Evolution of Shorter Therapy Nucleoside/NSSA Inhibitors Protease/NSSA Inhibitors Longer period for viruses to replica
Slide 15: Shorter Treatment Drives Increased Market Share
Ate Lol Shorter Treatment Drives Increased Market Share 2017 Annual Sales: $12.69 Billion 2018 Annual Sales: $8.3 Billion = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) = Merck (Zepatier) a J&J (Olysio) = AbbVie (Viekira, Mavyret) mAbbVie (Viekira, Mavyret) = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi)
Slide 16: CC-31244: HCV Non-Nucleoside Inhibitor (NNI)
N \ LT. CC-31244: HCV Non-Nucleoside Inhibitor (NNI) HCV GT1 — GT6 NS5B Polymerase Crystals eS ia o Next Generation Combination Therapy Potential Best-in-Class NNI ¢ Potential best-in-class HCV NNI with a cone Dose Treatment | Mirai Load strong profile (mg) Frequency | (1.og,,lU/ml) 4 ¢ Broad spectr
Slide 17: Cocrystal Pharma Phase 2a Completed
N S 1S! Cocrystal Pharma Phase 2a Completed N ° The treatment was well tolerated with no study discontinuations due to adverse events . Eight of 12 subjects (67%) achieved both SVR12 and SVR24, considered virologic cure Four patients had virologic relapse at Week 10, 4 weeks after completion of trea
Slide 18: Overview | Antiviral Programs: Influenza
18 Overview | Antiviral Programs: Influenza
Slide 19: Significant Unmet Need in Growing Influenza Market
POS Lol Significant Unmet Need in Growing Influenza Market Seasonal and pandemic infection 1 Billion po inon Up to 650,000 cases of severe cases annually? : illness annually’ deaths worldwide’ Current antiviral treatments are burdened by significant viral resistance ¢ Approved influenza therapies ha
Slide 20: Influenza Remains a Major U.S. and Global Concern
SS Lol Influenza Remains a Major U.S. and Global Concern Flu season deaths top 80,000 last year, CDC says ee Flu Season Off To US on track for one of Child Flu Deaths Hit Record TV the worst flu seasons SCI=NCE WYLRN arly start, And it i decease High for This Time of Year | | saison “= Gould Be Seve
Slide 21: Influenza A/B Merck Collaboration
POS Lol Influenza A/B Merck Collaboration & MERCK Proprietary Influenza A and B Crystals ° Broad spectrum, potent dual influenza A/B preclinical lead will be developed « Result of Cocrystal’s drug discovery platform technology * Binds to highly conserved site of influenza A and B replication complex
Slide 22: CC-42344: Influenza A Drug
LT. CC-42344: Influenza A Drug Potential for Cocktail Therapy Binds to the highly conserved pocket on replication enzyme Exhibits broad spectrum activity against seasonal and pandemic influenza strains Favorable preclinical safety profile and pharmacokinetic properties NEXT STEPS: ¥ Q2 2020 Secure S
Slide 23: CC-42344 Shows Strong Synergistic Effects with Approved Influenza Antivirals
roi CC-42344 Shows Strong Synergistic Effects with TF Approved Influenza Antivirals Polymerase Inhibitor Favipiravir ‘> on Se Cocrystal 42344 peated PA Inhibitor Neuraminidase Inhibitor C@CRYSTAL
Slide 24: CC-42344: Pharmacological, Safety, Toxicity, and PK Evaluations Completed
roi CC-42344: Pharmacological, Safety, Toxicity, and ——_ PK Evaluations Completed In vitro antiviral profiling against seasonal and pandemic influenza A strains Cytotoxicity including larger screen: HepG2/high content analysis and 13 cell lines Caco-2 bidirectional permeability CYP inhibition (HLM):
Slide 25: Overview | Antiviral Programs: Norovirus
25 Overview | Antiviral Programs: Norovirus
Slide 26: Norovirus: No Approved Treatment or Vaccine
\N ~“ Lol Norovirus: No Approved Treatment or Vaccine N Norovirus Polymerase and Protease Crystals ae <2] se $4.2 billion in direct health system costs! 700 million 19-21 million infections cases worldwide annually? in the U.S.2 400,000 56,000-71,000 hospitalizations emergency department visits in t
Slide 27: Cocrystal's Norovirus Program
N ¢ Cocrystal’s Norovirus Program I N Potent and broad-spectrum polymerase and protease inhibitors Structure-based lead discovery ongoing Licensed potent, broad spectrum protease inhibitors from KSURF NEXT STEPS: ¥ Q2 2020 File Additional Patent Application * Q4 2020 Complete Proof-of-Concept Animal
Slide 28: Well-Positioned for Growth
28 Well-Positioned for Growth
Slide 29: Growing Intellectual Property Portfolio
mS Growing Intellectual Property Portfolio xT « HCV ¢ Influenza A/B * NS5B (non-nucleoside inhibitor) ° Influenza A/B inhibitor * Issued patents in U.S. ° Pending applications in U.S. and * Pending applications in U.S. and worldwide worldwide « Pending U.S. provisional application ¢ Coronavirus * Is
Slide 30: Financial Snapshot
N S Ie Financial Snapshot: NASDAQ: COCP N Common shares Average 3 month outstanding daily volume2 Market cap! ¢ 53.3 MM Fully Diluted Shares ¢ No Preferred Shares Outstanding ¢ No Debt Outstanding 1: Based on May 4, 2020 closing price of $.89 per share; 2: Yahoo Finance, 3-month daily volume
Slide 31: Strategy Directed at Advancing Programs and Growing Value
A NS Lol Strategy Directed at Advancing Programs and Growing Value Advancing preclinical COVID-19 Coronavirus program by leveraging patent rights and compounds recently acquired from Kansas State University Research Foundation Ongoing collaboration with Merck has accelerated influenza A/B developmen
Slide 32: Thank you!
NASDAQ: COCP. cocrystalpharma.com C@CRYSTAL Thank you! PetieA ReM AS, I NC.